Navigation Links
Tailor-made Cancer Treatment for Multiple Myeloma Patients Offered by Mayo Clinic

Mayo Clinic Cancer Center, has singled out tumor specific alterations in cellular pathway by which drug bortezomib (Velcade) works.// This drug is administered to patients suffering from multiple myeloma.researchers have identified almost nine genetic mutations in cancer cells that might improve chances of patients responding to the agent.

These findings may help physicians to frame tailor treatment to patients with multiple myeloma, considered to be a cancer that is hard to treat.Multiple Myeloma affects plasma cells of the blood,and is the second most common blood cancer encountered in the United States. "Bortezomib seems to work in about one-third of patients who use it, but we have not been able to predict which ones," says the study's lead author, Leif Bergsagel, M.D., a hematologist at Mayo Clinic Arizona. "We now have identified a group that will likely respond because these nine mutations seem to be present in at least 25 percent of newly diagnosed patients.

"Now that we know the pathway the drug targets, and genetic mutations within this pathway that make patients respond better, we are working on a simple way to select those patients who are the best candidates for use of bortezomib," says Dr. Bergsagel.

In 2003, after only a four-month review, the Food and Drug Administration (FDA) approved use of bortezomib in patients who have failed other treatments for multiple myeloma. Later studies showed it lengthened survival by as much as six months. The drug was the first approved in a new class of agents known as proteasome inhibitors. Proteasomes are large protein groups inside cells that break down other proteins. Agents that inhibit the proteasome cause a buildup of proteins that affect many signaling cascades (various necessary biological processes). Bortezomib was initially thought to exert its activity by disrupting one of two known NF-êB (Nuclear Factor kappa B) pathways which keep cancer cells from self destructing t he first-discovered, or canonical, NF-êB pathway.

But through extensive genetic examination of 42 unique multiple myeloma cell lines and tumor samples taken from 68 patients, the investigators defined multiple genetic mutations in the other NF-êB pathway, the so-called non-canonical pathway. "These mutations make the tumor more dependent on that pathway, and consequently more susceptible to bortezomib treatment," said senior author Rafael Fonseca, M.D., also at Mayo Clinic in Arizona. "Identifying these mutations in patients will help us decide who should be treated with bortezomib, probably as an initial therapy," he says. The researchers are developing a test to check for activation of the non-canonical NF-êB pathway in patients. Now that the mutations have been identified, drug designers may be able to fashion new therapies that are more specific to these genetic alterations and, therefore, less toxic.

Dr. Bergsagel says. "These mutations represent good targets for drug development," he says.



Source-Eurekalert
ST
'"/>




Related medicine news :

1. The Age of Tailor-made Babies
2. Fibroids unlikely to Turn Cancerous
3. Virus Level could Predict Cervical Cancer Risk
4. Cancer Doctors Okays Controversial Prostate Therapy
5. Potential New Cancer Gene Identified
6. Consensus on "Combination Therapy" for Breast Cancer
7. Cancers of Colon & Rectum linked to Cigarette Smoking
8. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
9. The Cancer Rumour mill working over time
10. Cancer drugs in development nearly doubled since 1995
11. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... ... January 23, 2017 , ... Steviva Ingredients, makers ... under the USDA National Organic Program (NOP) for its Portland SQF Level 2 ... organic production and handling systems to complement our current rigorous food-safety management systems,” ...
(Date:1/23/2017)... , ... January 23, 2017 , ... “The Inn at the Mill”: a story ... fears in her quest to become happy and content. , “The Inn at the ... has also lived in Germany and Vermont and is now living in Berks County on ...
(Date:1/23/2017)... ... 23, 2017 , ... Valentine’s Day is a time when many people celebrate romance and love ... may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering ... free. Or, spend $200 and get $50 free. , “A lot of people just ...
(Date:1/21/2017)... ... 21, 2017 , ... Caronlab Australia, an Australian company known for health and ... Hilton Head, SC, where it benefited from outstanding meetings with major retail buyers. , ... wellness products. At this trade show, the company had the chance to demonstrate its ...
(Date:1/21/2017)... Barbara, CA (PRWEB) , ... January 21, 2017 ... ... its Director of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for ... festivities for alumni, family, friends, and community. “Coming Home 2017” will be ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  Based on its ... & Sullivan recognizes Ansell, a global leader in ... Sullivan Company of the Year Award. Ansell,s comprehensive ... a wide global footprint have placed it in ... protection market. The Company,s established product line and ...
(Date:1/23/2017)... , Jan. 23, 2017 Research and ... Market - Forecast to 2021" report to their offering. ... The interventional radiology ... from USD 6.35 Billion in 2016, at a CAGR of 4.8%. ... The major factors driving the growth of this market ...
(Date:1/23/2017)... Jan. 23, 2017 MouthWatch LLC announced today that ... ranked as the best intraoral camera on DentalCompare,s list of ... spot overall. The #1 product was the CollaPlug Absorbable ... intraoral camera was "…incredibly popular because it is by far ... a small sticker price, it doesn,t sacrifice quality imaging." ...
Breaking Medicine Technology: